Zilico receives funding to develop diagnostic device for oral cancer

Zilico Ltd has begun development work on a medical device which uses Electrical Impedance Spectroscopy (EIS) in the detection and diagnosis of oral cancer following funding from the Technology Strategy Board, the UK’s innovation agency.

The two awards are from the Biomedical Catalyst Feasibility and Smart Funds. The funds will help support an in-depth analysis of the UK market, deliver a product specification for an oral diagnostic device and a protocol for a multi-centre trial.

The funding builds on the proof-of-concept study that was recently presented and is part of a wider development programme leading to a multi-centre trial. The awards will help support development projects worth £160k.

Zilico’s lead product ZedScan uses its proprietary EIS technology to detect dysplasia and cancer of the cervix. As oral cancer follows a similar neoplastic pathway to that of the cervix, EIS can be used to detect changes in the oral epithelium as cells progress from normal to precancerous and then to cancerous.

The University of Sheffield’s Professor of Oral Medicine, Martin Thornhill, presented on the use of EIS in the detection and diagnosis of oral cancer and dysplasia to the most influential group of oral medicine experts in America last year.

Professor Thornhill’s presentation, Use of Impedance Spectroscopy to Detect Potentially Malignant Oral Lesions, was delivered at the 67th Annual Meeting of the American Academy of Oral Medicine (AAOM) in San Antonio, Texas. The study on 50 patients was the result of a collaboration between the University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust and Zilico Ltd.

The presentation abstract was published in the Oral Surgery, Oral Pathology, Oral medicine and Oral Radiology Journal in September 2013.  The full paper describing the study has been accepted for publication in the peer-reviewed Journal of Nanomedicine.

Zilico Chief Executive Sameer Kothari said:

We are delighted to have secured this funding, which will allow us to build on the proof-of concept study and positive feedback the data received at last year’s AAOM.

We are now well placed to further develop the device and assess it in a multi-centre clinical study. There is a clear clinical need for a more accurate diagnostic in the patient pathway.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Zilico. (2019, June 20). Zilico receives funding to develop diagnostic device for oral cancer. News-Medical. Retrieved on October 11, 2024 from https://www.news-medical.net/news/20140723/Zilico-receives-funding-to-develop-diagnostic-device-for-oral-cancer.aspx.

  • MLA

    Zilico. "Zilico receives funding to develop diagnostic device for oral cancer". News-Medical. 11 October 2024. <https://www.news-medical.net/news/20140723/Zilico-receives-funding-to-develop-diagnostic-device-for-oral-cancer.aspx>.

  • Chicago

    Zilico. "Zilico receives funding to develop diagnostic device for oral cancer". News-Medical. https://www.news-medical.net/news/20140723/Zilico-receives-funding-to-develop-diagnostic-device-for-oral-cancer.aspx. (accessed October 11, 2024).

  • Harvard

    Zilico. 2019. Zilico receives funding to develop diagnostic device for oral cancer. News-Medical, viewed 11 October 2024, https://www.news-medical.net/news/20140723/Zilico-receives-funding-to-develop-diagnostic-device-for-oral-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pioneering diagnostic system for cervical cancer to be on display at MEDICA 2016